{
  "@context": "https://schema.org/",
  "@type": "MedicalCondition",
  "@id": "aku:vascular:thrombophilia:lupus-anticoagulant",
  "name": "Lupus Anticoagulant",
  "alternateName": [
    "LA",
    "Lupus Inhibitor",
    "Antiphospholipid Antibody"
  ],
  "description": "An antiphospholipid antibody that paradoxically causes thrombosis despite prolonging in vitro clotting times. Part of the antiphospholipid syndrome (APS). Strongly associated with both arterial and venous thrombosis.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "D68.62",
      "codingSystem": "ICD-10-CM"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "40929003",
      "codingSystem": "SNOMED-CT",
      "name": "Lupus anticoagulant"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/dvt/thrombophilia",
    "type": "definition",
    "subtype": "acquired_thrombophilia",
    "difficulty": "advanced",
    "board_yield": "HIGH"
  },
  "pathophysiology": {
    "mechanism": {
      "in_vitro": "Antibodies bind phospholipids used in clotting assays, prolonging aPTT",
      "in_vivo": "Antibodies bind endothelial cell phospholipids, activating endothelium, platelets, and complement - NET PROTHROMBOTIC effect"
    },
    "paradox": "Prolongs clotting times in test tube but causes clots in patients",
    "target_antigens": [
      "Beta-2 glycoprotein I",
      "Prothrombin",
      "Phosphatidylserine",
      "Cardiolipin"
    ],
    "associations": {
      "primary_aps": "No underlying autoimmune disease",
      "secondary_aps": "Associated with SLE or other autoimmune disease",
      "catastrophic_aps": "Rare, acute multi-organ failure from widespread thrombosis"
    }
  },
  "clinical_features": {
    "thrombosis": {
      "venous": "DVT, PE, hepatic vein, renal vein, cerebral venous",
      "arterial": "Stroke, TIA, MI, digital ischemia, livedo reticularis",
      "unique": "BOTH arterial AND venous thrombosis can occur - unusual for thrombophilia"
    },
    "pregnancy_complications": [
      "Recurrent early pregnancy loss (<10 weeks)",
      "Fetal death (>10 weeks)",
      "Severe preeclampsia",
      "HELLP syndrome",
      "Placental insufficiency"
    ],
    "triple_positive_aps": {
      "definition": "Positive for lupus anticoagulant + anticardiolipin + anti-beta-2-GP1",
      "significance": "Highest thrombotic risk, highest recurrence risk",
      "management": "Warfarin preferred over DOACs"
    },
    "other_manifestations": [
      "Livedo reticularis",
      "Thrombocytopenia (mild)",
      "Cardiac valve vegetations (Libman-Sacks)",
      "Sneddon syndrome (livedo + stroke)"
    ]
  },
  "diagnosis": {
    "laboratory_criteria": {
      "lupus_anticoagulant": {
        "step_1": "Prolonged phospholipid-dependent clotting test (aPTT or dRVVT)",
        "step_2": "Mixing study - does NOT correct (inhibitor present)",
        "step_3": "Phospholipid neutralization - normalizes with excess phospholipid",
        "note": "dRVVT (dilute Russell viper venom time) is most specific"
      },
      "other_antibodies": [
        "Anticardiolipin IgG/IgM (medium-high titer)",
        "Anti-beta-2-glycoprotein I IgG/IgM"
      ]
    },
    "confirmatory": "Persistent positivity on two occasions 12 weeks apart",
    "sapporo_criteria": {
      "clinical": "Vascular thrombosis OR pregnancy morbidity",
      "laboratory": "Persistent antiphospholipid antibodies (12 weeks apart)"
    }
  },
  "management": {
    "acute_vte": "Heparin (UFH or LMWH) - lupus anticoagulant may affect aPTT monitoring",
    "long_term": {
      "first_vte": "Indefinite anticoagulation with warfarin (INR 2-3)",
      "triple_positive": "Warfarin preferred - DOACs show higher recurrence in trials",
      "arterial_thrombosis": "Warfarin INR 2-3 + aspirin (or INR 3-4)"
    },
    "pregnancy": {
      "prophylaxis": "LMWH + low-dose aspirin throughout pregnancy",
      "postpartum": "Continue anticoagulation 6 weeks postpartum"
    },
    "doac_caution": "TRAPS trial showed higher arterial events with rivaroxaban in triple-positive APS"
  },
  "clinical_pearls": [
    "Paradox: Lupus anticoagulant prolongs aPTT but causes CLOTS, not bleeding",
    "Only thrombophilia causing both arterial AND venous thrombosis",
    "Triple-positive APS = highest risk, use warfarin not DOACs (TRAPS trial)",
    "Name is misleading - most patients do NOT have lupus"
  ],
  "semantic_relations": {
    "broader": [
      "aku:vascular:thrombophilia:acquired"
    ],
    "narrower": [],
    "related": [
      "aku:vascular:thrombophilia:antiphospholipid-syndrome",
      "aku:vascular:anticoagulation:warfarin",
      "aku:vascular:stroke:aps-related"
    ]
  },
  "learning_objectives": [
    "Explain the paradox of lupus anticoagulant causing thrombosis despite prolonging clotting times",
    "Describe the diagnostic criteria for antiphospholipid syndrome",
    "Justify the preference for warfarin over DOACs in triple-positive APS"
  ],
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T01:36:00.000Z",
    "updated": "2026-01-06T01:36:00.000Z",
    "contributors": [
      "copilot",
      "quality-enhancement-agent"
    ],
    "status": "peer-reviewed",
    "confidence": 0.95,
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). aku:vascular:thrombophilia:lupus-anticoagulant. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Concept",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}